Impact Evaluation of Personalized Oral Hygiene Education on Periodontal Patients Stage I/II/III (HygParo)
Evaluation of personalized oral hygiene education on plaque accumulation and gingival inflammation in periodontal patients stage I/II/III.
Evaluation of personalized oral hygiene education on clinical attachment level in periodontal patients stage I/II/III.
Evaluation of personalized oral hygiene education on the psychological determinants described by the Health Action Process Approach (HAPA) and the mediating role of these psychological determinants in oral hygiene habits and clinical parameters in periodontal patients stage I/II/III.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Olivier HUCK
- Phone Number: +33 3 88 11 69 47
- Email: olivier.huck@chru-strasbourg.fr
Study Locations
-
-
-
Strasbourg, France, 67091
- Les Hopitaux Universitaires de Strasbourg
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion criteria:
- ≥ 18 years old
- Subject having signed an informed consent
- Subjects with periodontal disease Stage I/II/III :
- ≥ 15 teeth/implants
- Bleeding index at ≥ 25%
- Plaque index ≥ 20%
- Not requiring antibiotic prophylaxis prior to periodontal treatment.
- Not having received surgical periodontal treatment in the last 12 months.
- Smokers of ≤10 cigarettes/day
Exclusion criteria:
- <15 teeth/implants
- Physical or mental disability that does not allow for the performance of oral hygiene procedures.
- Chronic progressive pathology (diabetes...) / immunodeficiencies (HIV...)/ systemic infections.
- Ongoing drug treatment leading to a significant change in the periodontal condition (anti-epileptics, calcium antagonists, immunosuppressants, hormonal treatments, etc.).
- Ongoing drug treatment that can influence the periodontal condition (anti-inflammatory drugs, antibiotics)
- Patients with severe xerostomia or with Gougerot-Sjögren's syndrome.
- Subjects undergoing treatment for cancer
- Pregnant or breastfeeding women
- Smokers of > 10 cigarettes/day
- Impossibility to give information about the subject (subject in an emergency situation, difficulties in understanding the French language, etc.).
- Subject under safeguard of justice
- Subject under guardianship or curatorship
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Control group: Dental model
Patients diagnosed with periodontal disease stage I/II/III
|
- Patients receive a demonstration of plaque control methods (modified Bass dental brushing technique and the use of the electric toothbrush) using a dental model.
|
|
Computer-assisted teaching format group
Patients diagnosed with periodontal disease stage I/II/III
|
- Patients receive a Powerpoint presentation containing:
|
|
Plaque-disclosing group
Patients diagnosed with periodontal disease stage I/II/III
|
- Patients place a few drops of a plaque-disclosing solution on the tongue and run the tongue over all the teeth and gums.
With the aid of a hand mirror, patients can observe the stained plaque residue on their teeth
|
|
Intra-oral Camera group
Patients diagnosed with periodontal disease stage I/II/III
|
- An ACTEON Soprocare® intraoral camera is used during the examination and explanation of oral hygiene strategies.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Evaluation of the plaque index
Time Frame: 3 months
|
Plaque Index (Loë and Silness, 1963): Six surfaces per tooth (buccal, mesio-buccal, disto-buccal, lingual, mesio-lingual and disto-lingual) are examined in every permanent tooth (except for third molars). Each tooth is assessed with a score between 0 and 3.
|
3 months
|
|
Evaluation of the gingival index
Time Frame: 3 months
|
Gingival Index (Loë 1967): Six surfaces per tooth (buccal, mesio-buccal, disto-buccal, lingual, mesio-lingual and disto-lingual) are examined in every permanent tooth (except for third molars).
|
3 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Evaluation of probing pocket depth
Time Frame: 3 months
|
Probing pocket depth (distance from the top of the marginal gingiva to the bottom of the pocket)
|
3 months
|
|
Evaluation of the gingival attachment level
Time Frame: 3 months
|
Gingival attachment level (distance separating the cemento-enamel junction from the bottom of the pocket)
|
3 months
|
|
Psychological determinants of the HAPA (Health Action Process Approach)
Time Frame: 3 months
|
Change in the psychological determinants of the HAPA questionnaire adapted to oral health, using a 7-point Likert scale from "strongly disagree" (1) to "strongly agree" (7)
|
3 months
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Anticipated)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 8091
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Periodontal Disease Stage I/II/III
-
NCT07590089CompletedPeriodontitis | Periodontitis Stage I | Periodontitis Stage II | Periodontitis Stage III
-
NCT07517211Not yet recruitingClinical Stage III Gastric Cancer AJCC v8 | Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 | Clinical Stage I Esophageal Adenocarcinoma AJCC v8 | Clinical Stage I Esophageal Squamous Cell Carcinoma AJCC v8 | Clinical Stage I Gastric Cancer AJCC v8 | Clinical Stage II Esophageal Adenocarcinoma AJCC v8 | Clinical Stage II Esophageal Squamous Cell Carcinoma AJCC v8 | Clinical Stage II Gastric Cancer AJCC v8 | Clinical Stage III Esophageal Adenocarcinoma AJCC v8 | Clinical Stage III Esophageal Squamous Cell Carcinoma AJCC v8
-
NCT07517991CompletedPeriodontitis | Periodontitis Stage I | Periodontitis Stage II
-
NCT07599657RecruitingPeriodontitis | Periodontitis Stage II | Periodontitis Stage III
-
NCT07439484Not yet recruitingClinical Stage III Gastric Cancer AJCC v8 | Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 | Clinical Stage I Esophageal Squamous Cell Carcinoma AJCC v8 | Clinical Stage I Gastric Cancer AJCC v8 | Clinical Stage II Esophageal Adenocarcinoma AJCC v8 | Clinical Stage II Esophageal Squamous Cell Carcinoma AJCC v8 | Clinical Stage II Gastric Cancer AJCC v8 | Clinical Stage III Esophageal Adenocarcinoma AJCC v8 | Clinical Stage III Esophageal Squamous Cell Carcinoma AJCC v8 | Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8
-
NCT07505251Not yet recruitingPeriodontitis Stage II | Periodontitis Stage III | Periodontitis Stage IV
-
NCT04007770Active, not recruitingGynecologic Cancer | Stage I Breast Cancer | Stage II Breast Cancer | Stage I Prostate Cancer | Stage II Prostate Cancer | Stage III Prostate Cancer | Stage III Breast Cancer | Stage III Gynecologic Cancer | Stage III Colorectal Cancer | Stage I Colorectal Cancer
-
NCT02213913CompletedExtranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Splenic Marginal Zone Lymphoma | Waldenström Macroglobulinemia | Cutaneous B-cell Non-Hodgkin Lymphoma | Intraocular Lymphoma | Small Intestine Lymphoma | Testicular Lymphoma | B-cell Chronic Lymphocytic Leukemia | Stage III Adult Diffuse Large Cell Lymphoma
-
NCT06967402Not yet recruitingPeriodontitis | Periodontitis Stage II | Periodontitis Stage III
-
NCT07405476RecruitingColorectal Carcinoma | Colon Carcinoma | Rectal Carcinoma | Stage III Colon Cancer AJCC v8 | Stage III Rectal Cancer AJCC v8 | Stage III Colorectal Cancer AJCC v8 | Stage I Colorectal Cancer AJCC v8 | Stage II Colorectal Cancer AJCC v8 | Stage II Rectal Cancer AJCC v8 | Stage I Rectal Cancer AJCC v8
Clinical Trials on Control group: Dental Model
-
NCT04088994CompletedMotor Activity | Hemiplegic Cerebral Palsy
-
NCT05311410RecruitingSARS-CoV2 Infection | Viral Load | Oral Diseases | Dental Treatment
-
NCT06581510Recruiting
-
NCT07348549Enrolling by invitationNursing Education | Learning Process in Nursing Graduation | Learning Techniques
-
NCT03913416Not yet recruiting
-
NCT05304507Completed
-
NCT04955860CompletedDental Malocclusion | Maxillary Anomaly | Crossbite (Anterior) (Posterior)
-
NCT04885348CompletedDental Caries in Children
-
NCT05434442CompletedTracheostomy | Aspiration | Family Caregivers
-
NCT05211999Completed